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Abstract
Background: Since mature erythrocytes are terminally differentiated cells without nuclei and organelles, it is commonly
thought that they do not contain nucleic acids. In this study, we have re-examined this issue by analyzing the transcriptome
of a purified population of human mature erythrocytes from individuals with normal hemoglobin (HbAA) and homozygous
sickle cell disease (HbSS).
Methods and Findings: Using a combination of microarray analysis, real-time RT-PCR and Northern blots, we found that
mature erythrocytes, while lacking ribosomal and large-sized RNAs, contain abundant and diverse microRNAs. MicroRNA
expression of erythrocytes was different from that of reticulocytes and leukocytes, and contributed the majority of the
microRNA expression in whole blood. When we used microRNA microarrays to analyze erythrocytes from HbAA and HbSS
individuals, we noted a dramatic difference in their microRNA expression pattern. We found that miR-320 played an
important role for the down-regulation of its target gene, CD71 during reticulocyte terminal differentiation. Further
investigation revealed that poor expression of miR-320 in HbSS cells was associated with their defective downregulation
CD71 during terminal differentiation.
Conclusions: In summary, we have discovered significant microRNA expression in human mature erythrocytes, which is
dramatically altered in HbSS erythrocytes and their defect in terminal differentiation. Thus, the global analysis of microRNA
expression in circulating erythrocytes can provide mechanistic insights into the disease phenotypes of erythrocyte diseases.
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Introduction
Erythrocytes constitute more than 90% of the cell population in
the peripheral blood and are responsible for efficient gas exchange
in the human body. Mature erythrocytes are the end-products of a
highly regulated differentiation process that involves the gradual
loss of cellular organelles, a decline in nucleic acid content, and a
step-wise acquisition of erythrocyte characteristics [1]. One
striking feature of erythroid differentiation is that the nuclei are
extruded from cells as they differentiate into reticulocytes, the
immediate precursor of mature erythrocytes. While cytoplasmic
RNA and translation activities are still detectable in CD71+
reticulocytes, they fall below the detection limit as cells terminally
differentiate to become CD71- mature erythrocytes [2]. Since
hemoglobin makes up the majority of erythrocyte cellular proteins,
these cells are frequently thought to serve merely as inert and
passive containers of hemoglobins. However, their more dynamic
nature was suggested by the recent finding that erythrocytes can
mount cellular signaling and trigger functional responses during
physiological and pathological stresses [3,4]. This suggests that
erythrocytes have a more sophisticated intracellular environment
than previously appreciated.
Processes disrupting erythrocyte homeostasis lead to human
diseases that present huge economic and social challenges. Even
though erythrocyte diseases have been studied for a long time, our
current understanding of the erythrocyte still cannot fully explain
the multitude of clinical effects or the enormous clinical variation
seen in patients with these diseases. Global analysis of gene
expression using microarray technology holds great potential for
advancing our understanding of erythrocyte diseases. This
technology has led to an explosion of knowledge in understanding
pathogenic mechanisms and clinical heterogeneity in human
cancers. However, its application to erythrocyte diseases has been
limited by the long-held belief that mature erythrocytes lack RNA
expression. This belief is supported by the ability some RNA-
binding dyes (such as thiazole orange or methylene blue) to stain
reticulocytes but not erythrocytes, an observation which forms the
basis of the clinical utility of these dyes in distinguishing
reticulocytes from mature erythrocytes [5]. Furthermore, analysis
of RNA isolated from whole blood by PAXgene technology [6]
revealed no detectable contribution from erythrocytes. Only gene
signatures from neutrophils, lymphocytes and reticulocytes were
detected, even though erythrocytes are the predominant cell type
in the blood [7].
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2360Given the potential limitations of sensitivity and size bias for
these traditional means of isolating and characterizing erythrocyte
RNA, it remained possible that erythrocytes may contain RNA
species not previously identified. Here, we provide several lines of
evidence that human mature erythrocytes, although lacking in
ribosomal and large-sized RNAs, contain diverse and abundant
microRNAs. Our findings confirm the results of a recent study on
small RNA expression in Plasmodium falciparum that found several
microRNA species in peripheral erythrocytes [8]. Importantly, the
discovery of these microRNAs allowed us to use microarrays to
compare their expression in mature erythrocytes from normal
(HbAA) and homozygous sickle cell (HbSS) individuals and to
identify a link between the dysregulation of microRNA and the
pathogenesis of sickle cell disease (SCD).
Results
Purification of Human Mature Erythrocytes
To test for the possibility that mature erythrocytes contain
previously undetected RNAs, we developed a protocol to obtain a
pure population of mature erythrocytes by removing other blood
cells through a series of purification procedures (Fig 1A). Blood
collected from healthy volunteers first went through a PALL
PurecellNeo filter to remove most leukocytes and was then placed in
a Ficoll-hypaque density gradient to separate erythrocytes from
leukocytes and platelets. Finally, any remaining leukocytes (CD45+)
and reticulocytes (CD71+) in the packed erythrocyte pellets were
removed by magnetic immuno-depletion with AutoMacs.
The purity of the erythrocytes obtained by this method was
assessed with lineage-specific markers. Purified cells were 99.8%
positive for the erythrocyte marker CD235a, while negative for
leukocyte (CD45, CD16) and reticulocyte (CD71) markers (Fig 1B).
These results correlated well with molecular evidence for leukocyte
depletion, in that no CD45 mRNA was detected by RT-PCR
(Fig 1C). The absenceof reticulocytes inour erythrocyte preparations
was validated by the absence of positive cells when stained with new
methylene blue (Fig 1D) as well as routine reticulocyte analysis in the
clinical laboratory. Taken together, these results show that we were
able to obtain highly purified mature erythrocytes without significant
contamination of leukocytes and reticulocytes.
Identification and genomic characterization of
erythrocyte microRNAs
To ensure that RNAs of all sizes were recovered from
erythrocytes, we chose an RNA purification method designed
for microRNA isolation, capable of capturing RNAs as small as
Figure 1. The purification of human mature erythrocytes. (A) The purification scheme used to obtain mature erythrocytes and reticulocytes
from human blood. Assessment of the purified mature erythrocytes was then performed by examining the surface expression of indicated lineage
markers on whole blood (before purification–blue line) and purified erythrocytes (after purification–red line) with FACS–CD16, CD45, CD71 and
CD235a (B). (C) RT-PCR assay to evaluate the abundance of indicated transcripts (CD45, tRNA and beta-hemoglobin) in the RNA from purified
erythrocytes (RBC), peripheral blood mononuclear cells (PBMC) and whole blood. (D) New methylene blue stain of the CD71- erythrocytes (left) and
CD71+ reticulocytes (right) from two independent isolations.
doi:10.1371/journal.pone.0002360.g001
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obtained low but reproducible levels of RNAs from all mature
erythrocyte samples (N=21). The RNA yields ranged from 5–
10 mg RNAs from 10 ml of whole blood; by back-calculation,
considering the cell numbers and cell purification yield, with the
assumption of equal RNAs in all erythrocytes, the RNA content
was approximately 2–3610
24 pg/cell. This RNA content is
similar to platelets (3610
24 pg/cell), but significantly lower than
nucleated cells (5–9 pg/cell) [9]. To rule out the possibility that the
RNAs were from contaminating reticulocytes, we adopted an
alternative approach to separate reticulocytes from erythrocytes
with an arabinogalactan density gradient [10]. With this
independent approach of isolating mature erythrocytes, we
obtained a similar level of erythrocyte RNA.
We then used an Agilent bioanalyzer to compare the size
distribution of erythrocyte RNAs with leukocyte RNAs (Fig 2A).
Erythrocyte RNAs (Fig 2A, lane 2–4) did not contain the two
distinct ribosomal bands (28S and 18S) observed in simultaneously
prepared peripheral blood mononuclear cells (PBMC) (Fig 2A,
lane 5). Instead, erythrocyte RNAs was highly enriched for small-
sized RNAs of less than 200 base pairs, which were also present in
leukocyte RNAs but at a much lower level. These small-sized
RNAs were sensitive to treatment with RNAse and NaOH, while
resistant to DNAse treatment. The observed size range of
erythrocyte RNAs could represent several RNA species, including
microRNA, snoRNA, tRNA and degraded mRNAs. MicroRNAs
are evolutionarily conserved, small, non-coding RNA molecules
that play important regulatory roles in various biological processes
[11]. To assess the possibility that the small-sized RNAs contained
microRNAs, we utilized a spotted microRNA microarray platform
containing DNA oligonucleotides representing 196 human micro-
RNAs [12] to interrogate the microRNA contents of mature
erythrocytes and K562, an erythroleukemia cell line which
expresses many genes typical of an earlier stage of erythroid
differentiation. Equal amounts (40 ng) of fractionated RNAs from
three separately purified erythrocyte and two K562 samples were
labeled for microarray analysis. As shown in Fig 2A, the
hybridization result revealed abundant and diverse microRNAs
within the erythrocyte RNAs and 87 microRNAs whose
expression varied between erythrocyte and K562 more than 3
fold in at least two samples. When compared with K562 cells,
mature erythrocytes specifically expressed several microRNAs,
including several microRNAs in the let-7 family and several
microRNAs (miR-181A, miR-223, miR-15, miR-16) that have
been shown to play a role in the lineage differentiation in the
hematopoietic system [13].
To examine changes in microRNA expression levels during the
process of erythroid differentiation, we compared our array results
with microRNA expression in the differentiating hematopoietic
CD34+ cells described in the supplemental data of a study on
cancer microRNA expression [14]. Even though the CD34+ cells
did not reach the stage of reticulocytes at the end of this in vitro
differentiation process, most of the erythrocyte-specific micro-
RNAs found in our array analysis were upregulated during the
early stages of erythroid differentiation (Fig 2B). Similar sets of
microRNAs were also found in two other studies of microRNA
expression with different in vitro erythroid differentiation models
[15,16]. Despite the fact that erythrocytes are the predominant cell
type in the peripheral blood, the messenger RNA (mRNA) from
leukocytes contributes the majority of mRNA in whole blood,
since these nucleated cells have much higher RNA content [7].
Our finding of microRNA expression in erythrocytes prompted us
to test whether erythrocyte microRNA may contribute signifi-
cantly to the microRNA expression pattern seen in whole blood.
To test this possibility, RNAs from whole blood, erythrocytes, and
leukocytes from the same healthy normal individuals (N=3) were
fractionated and an equal amount of small-sized RNAs (,40 bp)
was labeled and interrogated with microRNA microarrays. The
unsupervised hierarchical clustering of these samples consistently
arranged whole blood samples and erythrocyte samples in the
same branch away from the leukocyte samples. This showed that
the whole blood microRNA expression pattern was similar to that
of erythrocytes and not that of leukocytes (Fig. 2C). This
observation is distinct from the results obtained with mRNA and
further highlights the important contribution of erythrocyte
microRNA to whole blood microRNA expression. Therefore,
leukocyte microRNAs represent a relatively minor portion of
whole blood microRNAs and are not likely to be the source of the
microRNAs we have discovered in mature erythrocytes. The
erythrocyte-specific microRNA gene cluster found when com-
pared with leukocytes (Fig 2C) contained the same sets of
erythrocyte-specific microRNAs seen when erythrocytes were
compared with K562 in the previous analysis (Fig 2B). We chose
six of erythrocyte-specific microRNAs and further validated their
abundant expression in erythrocytes by Northern blot (Fig 2D). All
of the tested microRNAs were present predominantly in their
mature form in the erythrocytes. No significant precursor
microRNAs or microRNA degradation products were noted in
the Northern blots.
Recently, a stem-loop real-time PCR technology has been
developed to determine microRNA expression levels, with a large
dynamic range [17] in minute amounts of samples [18].
Importantly, this technology relies on the specific finding of both
the 59 and 39 ends of microRNA and therefore detects only full
length mature microRNAs but not their precursors or partially
degraded products. We used this real-time RT-PCR assay to
determine the expression level of 192 mature microRNAs (for
which the assay was available) in 10 erythrocyte and 2 reticulocyte
samples to compare the microRNA expression for erythroid cells
at these two different differentiation stages. The reticulocytes were
obtained by additional purification with cell sorting using FACS
from the CD71+ fraction obtained during the process of mature
erythrocyte purification, based on CD71 immunodepletion
(Fig 1A). Out of 192 assayed microRNAs, 162 were highly
detectable (with cycle threshold (CT) ,35) in more than 75% of
the samples and were chosen for further analysis. This result
indicated that the reticulocytes and erythrocytes possess abundant
and diverse groups of microRNAs, which were full length mature
microRNAs instead of partially degraded microRNA remnants.
Out of these 162 microRNAs, which were expressed in
erythrocytes, 136 of them were represented on our microRNA
microarrays and 130 exhibited hybridization signals in the Cy5
channel more than 2 fold above background. MicroRNAs in the
let-7 family were among the most abundant transcripts in real-time
PCR assays, consistent with our results from microarrays. We
normalized the expression levels of the 162 microRNAs against
miR-152 expression levels in all 12 samples for further analysis.
We used miR-152 as an endogenous normalization control, since
its expression was not altered during different stages of erythroid
differentiation [14], and it showed the least amount of variation
across 40 different human tissues in a separate microRNA real-
time RT-PCR profiling study (Applied Biosystems, unpublished
data). The resulting negative normalized Ct value (as represented
by 2DCti=2(Cti2CtmiR152)) of all remaining 161 microRNAs
indicated the expression level of each microRNA (detailed in
supplemental website). Unsupervised hierarchical clustering based
on the expression values grouped all samples into two separate
branches–one branch containing all freshly isolated erythrocytes
Erythrocyte miRNA Expression
PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2360and another branch containing reticulocytes (displayed as a heat
map in Fig 3A). Therefore, mature erythrocytes have a microRNA
expression pattern distinct from that of reticulocytes. We have
further applied Significant Analysis of Microarrays (SAM) [19] in
a supervised analysis and found that 83 microRNAs were
expressed in a reticulocyte-enriched fashion (Fig 3A and
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Figure 2. Human mature erythrocytes contain abundant and diverse microRNAs. (A) The size distribution of RNAs of three independent
erythrocyte samples (lanes 2–4 labeled RBC #1,2,3) and one PBMC sample (lane 5 labeled as PBMC) were assessed with Agilent Bioanalyzer with
indicated size markers (lane 1 as indicated). (B) Left: the microRNA expression pattern obtained with microRNA microarrays of three mature
erythrocyte samples was compared to that of two erythroleukemia K562 cell lines. Right: the expression of erythrocyte-specific microRNAs in the
CD34+ erythroid progenitor cells at indicated stages of erythroid differentiation in a previously published study [14]. (C) The microRNA expression of
whole blood was similar to erythrocytes and grouped together in one branch away from leukocytes with unsupervised hierarchical clustering.
Selected erythrocyte-specific microRNAs were shown. (D) The expression of U6 and indicated microRNAs in K562 cells and erythrocytes was assessed
by Northern blots with the migration position of U6 and mature microRNAs indicated. The position of U6 RNA and microRNAs (indicated bars on the
right) were established with synthesized DNA oligonucleotides included in the Northern blots.
doi:10.1371/journal.pone.0002360.g002
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microRNAs of the let-7 family as well as miR-221 and miR-222,
two microRNAs whose downregulation during erythroid differ-
entiation is essential this process [20].
To determine whether the global analysis erythrocyte micro-
RNA expression can lead to novel insights in human erythrocyte
diseases, we recruited 12 individuals with HbSS (homozygous
sickle cell disease) and 7 race-matched individuals with HbAA
(normal hemoglobin). We used the three-step purification method
based on both density separation and immuno-depletion of the
reticulocyte population (Fig 1A) to isolate erythrocytes for RNA
analysis since the density-only approach may suffer potential
reticulocyte contamination in ‘‘dense’’ cell fractions from the
HbSS patients. Using FACS, methylene blue stain and clinical
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Figure 3. Erythrocyte microRNA show differentiation- and disease-specific expression. (A) The expression value of microRNA expression
in the two reticulocytes (pink) and ten erythrocytes (red) assessed with TaqMan real-time assay. The expression levels of the 83 microRNAs identified
by SAM as reticulocyte-specific were shown with selected microRNAs indicated. (B, C) The erythrocyte microRNA expression obtained from 7 HbAA
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doi:10.1371/journal.pone.0002360.g003
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PLoS ONE | www.plosone.org 5 June 2008 | Volume 3 | Issue 6 | e2360laboratory techniques we confirmed that the purification scheme
would allow us to obtain a mature erythrocyte population from
HbSS individuals, who typically have higher levels of reticulocytes
than normal individuals. The microRNA expression pattern of the
purified erythrocytes from these 19 individuals was determined by
microRNA microarrays. The microRNA expression patterns in
HbSS and HbAA erythrocytes were distinct from each other and
were easily separated into two groups by unsupervised hierarchical
clustering (Fig. 3B) based on the 200 array elements (97
microRNAs) varying by more than 1.8 fold from the mean in
two samples. Several microRNAs (miR-320, let-7s, miR-181, miR-
141) were over-represented in the HbAA erythrocytes, while other
microRNAs (miR-29a, miR-144, miR-451, miR-140) were over-
represented in the HbSS erythrocytes (Fig. 3C). To compare the
differentiation status of the two sample groups, we extracted
expression values of the 83 reticulocyte-enriched microRNAs
(Fig 3A) and found that their expression level was significantly
Table 1. The 83 microRNAs with preferential expression in
reticulocytes.
Reticulocyte-specific microRNAs
hsa-miR-125b
hsa-miR-321
hsa-miR-193
hsa-miR-145
hsa-miR-128b
hsa-miR-221
hsa-let-7f
hsa-miR-99b
hsa-let-7a
hsa-let-7g
hsa-miR-19a
hsa-miR-122a
hsa-miR-146
hsa-miR-129
hsa-miR-151
hsa-miR-373
hsa-miR-188
hsa-miR-197
hsa-miR-187
hsa-let-7d
hsa-miR-339
hsa-let-7c
hsa-let-7e
hsa-miR-338
hsa-miR-143
hsa-let-7b
hsa-miR-196b
hsa-miR-370
hsa-miR-93
hsa-miR-345
hsa-miR-103
hsa-miR-125a
hsa-miR-302a*
hsa-mir-196-1
hsa-miR-198
hsa-miR-216
hsa-miR-199a
hsa-miR-139
hsa-miR-196
hsa-miR-373*
hsa-miR-330
hsa-miR-337
hsa-miR-10b
hsa-miR-324-3p
hsa-miR-222
hsa-miR-184
hsa-let-7i
hsa-miR-189
hsa-miR-26b
Table 1. cont.
Reticulocyte-specific microRNAs
hsa-miR-196a
hsa-miR-19b
hsa-miR-342
hsa-miR-135a
hsa-miR-199a*
hsa-miR-200a
hsa-miR-105
hsa-miR-210
hsa-miR-107
hsa-miR-147
hsa-miR-20
hsa-miR-325
hsa-miR-98
hsa-miR-138
hsa-miR-194
hsa-miR-218
hsa-miR-23b
hsa-miR-135b
hsa-miR-137
hsa-miR-108
hsa-miR-15b
hsa-miR-211
hsa-miR-340
hsa-miR-220
hsa-mir-124b
hsa-miR-195
hsa-miR-185
hsa-miR-29a
hsa-miR-302b*
hsa-miR-95
hsa-miR-223
hsa-miR-101
hsa-miR-30c
hsa-miR-27a
doi:10.1371/journal.pone.0002360.t001
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This result suggested that HbSS erythrocytes exhibited an
expression pattern closer to reticulocytes, consistent with their
relatively younger age due to their shorter life span (,20 vs. 120
days) [1]. There were also many other differences in the
microRNA expression patterns of HbSS and HbAA erythrocytes
that may not related to differentiation stages or erythrocyte ages.
The basis for these differences in microRNA expression is
currently unknown.
miR-320 dysregulation and CD71 phenotypes in HbSS
individuals
Although the high number of CD71 positive reticulotyces
(reticulocytosis) seen in HbSS individuals is thought to reflect
increased erythropoiesis in response to hemolysis, we questioned
whether there might also be a defect in terminal differentiation in
HbSS reticulocytes for which microRNAs play a role. CD71
(transferrin receptor) is important both in the capturing of
transferrin/iron complex and the most relevant differentiation
marker for the terminal differentiation. Given the importance of
RNA-binding proteins in the regulation of CD71 expression at the
post-transcriptional level where microRNAs typically function
[21]. To test this possibility, we placed purified CD71+
reticulocytes in a previously described in vitro differentiation model
[22]. Reticulocytes from all four healthy donors underwent
successful terminal differentiation within 48 hours, as evidenced
by loss of surface expression of CD71, disappearance of new
methylene blue staining, decrease in mean corpuscular volume
(MCV) as reflected in the increase in mean corpuscular
hemoglobin concentration (MCHC) (Fig 4A and Fig S1) [22,23].
In contrast, reticulocytes from all three tested HbSS individuals
failed to manifest these changes of terminal differentiation; they
had persistent surface expression of CD71 (p=0.0064) and no
changes in MCHC during the 48 hours of incubation (Fig 4A and
Fig S1). This result indicated there was a defect in terminal
differentiation in the HbSS reticulocytes and was consistent with
our observation that HbSS erythrocytes appeared to have a less
differentiated phenotypes.
To evaluate the potential role for dysregulated microRNAs in
the defective downregulation of CD71 in HbSS reticulocytes, we
used several predictive algorithms to identify the microRNAs likely
to regulate the 39UTR of CD71 [24–26]. MiR-320 was predicted
to regulate CD71 by all three predictive algorithms (TargetScans
[24], PicTar [25] and miRanda [26]) with a perfect match
between its ‘‘seed’’ sequence (59- GUCGAAAA-39, nucleotides 2–
8) and the regulatory region in the CD71 39 UTR (CAGCTTTT,
2693 to 2700 of CD71 mRNA) that is conserved in five species
(Fig 4B). Furthermore, the miR-320 expression level, which was
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HbSS erythrocytes (Fig 4C, D), consistent with a possible role in
the defective repression of CD71 seen in HbSS cells. The miR-320
expression level did not change significantly between reticulocyte
and erythrocyte samples in our real-time RT-PCR analysis of
HbAA cells (Fig 4E).
To directly test the functional role of miR-320 during terminal
differentiation, we developed a transfection technique that allowed
us to elevate and reduce the levels of selected microRNAs in
reticulocytes. Using a modified protocol with fluorescently labeled
oligonucleotides and lipofectamine, we achieved a transfection
efficiency of 40–50% in both erythrocytes and reticulocytes
(Fig 5A). When synthesized mature miR-320 was transfected into
reticulocytes, we detected a three-fold increase in miR-320
expression with real-time RT-PCR (Fig 5B). On the other hand,
the transfection of LNA antisense oligonucleotides against miR-
320 led to 80% reduction in miR-320 levels (Fig 5B). To
investigate the function of miR-320 during reticulocyte terminal
differentiation, we inhibited miR-320 function by transfecting
either LNA antisense oligonucleotides against miR-320 or a
scrambled sequence LNA oligonucleotide into HbAA reticulocytes
before culturing them for in vitro terminal differentiation. While
reticulocytes transfected with the scrambled sequence LNA
oligonucleotide underwent normal CD71 downregulation, miR-
320 inhibition by the antisense oligonucelotide led to a persistent
high expression of CD71 (Fig 5C, D) in three separate experiments.
In addition, miR-320 inhibition in reticulocytes caused significant
cell death and led to fewer cell numbers when compared with cells
transfected with the scrambled oligonucleotide or with miR-20a
antisense oligonucleotides (Fig 5E, left). The effect was stage-specific,
since mature erythrocytes were not sensitive to the same treatment
(Fig 5E). These results indicated an essential role for miR-320 in
maintaining erythrocyte homeostasis during terminal differentiation
in normal reticulocytes. The phenotype of miR-320 inhibited
normal cells resembled that of HbSS cells, including defective
maturation and decreased survival. Thissuggested that low miR-320
expression may have a role in the dysregulated maturation and
decreased cell survival seen in SCD [1].
To evaluate whether CD71 was a direct target of miR-320, we
generated CMV-based expression constructs containing the miR-
451 and miR-320 genomic sequences and then tested for their
ability to specifically suppress expression from their respective
‘‘indicator’’ reporter constructs containing two copies of identical
miR-451 or miR-320 target sequences in a specific manner
(Fig 5F). A 453bp region of the CD71 39UTR (2547–2999 bp of
CD71 mRNA) was then amplified and placed downstream of the
luciferase reporter gene (Fig 5G). When this reporter construct was
co-transfected into K562 cells with expression constructs encoding
miR-320, miR-451 or empty vectors, we found that only miR-320,
but not miR-451 or empty vectors, repressed its activity (Fig 5G,
left). This miR-320-mediated repression was dependent on the
predicted miR-320 target site in the CD71 39UTR since a three
base pair change in this site abolished miR-320-mediated
repression (Fig 5G, right). Collectively, these results indicated that
CD71 was a direct target of miR-320 via the interaction between
its 39UTR and the miR-320 seed sequence.
To further validate the miR-320/CD71 interaction, we
overexpressed miR-320 in K562 cells and examine their influence
on surface CD71 expression. Overexpression of miR-320 in K562
cells led to a significantly lower level of CD71 when compared
with control transfection with empty vectors (Fig 5H). Taken
together, these results showed that miR-320 can directly regulate
the expression of CD71 and suggested that the poor expression of
miR-320 in HbSS cells is associated with their persistently high
CD71 level during terminal differentiation. In addition to CD71,
miR-320 was also predicted by TargetScanS [24] and PicTar to
target other mRNAs (Table S1, S2 [1]), including ETS2 (v-ets
erythroblastosis virus E26 oncogene homolog 2) and EPB41L5
(erythrocyte membrane protein band 4.1 like 5), two mRNA
encoding proteins important for erythrocyte biology
Discussion
In this study, we have presented several lines of evidences for the
presence of diverse microRNA in the mature erythrocytes. In gene
expression studies of enucleated cells with low RNA content (such
as erythrocytes, reticulocytes and platelets) [2,9,27,28], one
important concern is that a minority of contaminating nucleated
cells with high RNA content (leukocytes) may distort the observed
gene expression patterns. We do not believe that such contam-
ination has significantly affected this study, because of the
following observations. First, we have employed two different
purification schemes, composed of three levels of cell separation
based on cell density and surface expression to remove most
leukocytes, platelets and reticulocytes, to obtain the mature
erythrocytes used for expression analysis. We confirmed the purity
of the resulting mature erythrocytes by FACS, methylene blue
staining and molecular analysis of isolated RNAs. Second, the size
distribution and characteristics of the isolated erythrocyte RNAs
were significantly different from that of all nucleated cells–
uniquely enriched for small RNA species without prominent bands
of ribosomal RNAs. Third, when microRNAs from whole blood
were compared with leukocytes and mature erythrocytes, the
expression pattern of whole blood, even without leukocyte
depletion, was derived mainly from erythrocytes instead of
leukocytes. The microRNA expression pattern of mature eryth-
rocytes was also different from reticulocytes using microRNA real-
time RT-PCR assays. Taken together, these results indicate that
the expression of these microRNAs is indeed from mature
erythrocytes and not from other ‘‘contaminating’’ cells. Knowl-
edge of erythrocyte microRNA is also important to investigators
who are interested in leukocyte microRNAs, as it is now clear that
they must avoid the significant and unexpected bias caused by
erythrocyte microRNAs.
The human erythrocyte is one of the most studied cell types and
is often used as a model system to understand the general
principles of molecular genetics, biochemistry, membrane biology
and cell physiology. However, our understanding of erythrocytes
and the diseases that affect them is still incomplete. The
unexpected discovery of microRNAs in erythrocytes, consistent
with a previous study of parasitized red cells [8], adds a new
dimension to erythrocyte characterization and has the potential to
enhance our understanding of their phenotypic alterations during
physiological and pathological adaptations. As a step toward
realizing this potential, we used microarrays to analyze erythrocyte
microRNA gene expression in SCD to establish a connection
between microRNA dysregulation and the certain disease
phenotypes of SCD. Several recent studies have analyzed
microRNA expression on a global scale during in vitro erythroid
differentiation [15,16,29]. Although these differentiation models
do not lead to terminally differentiated erythrocytes analyzed in
our study, we note a high degree of similarity in the microRNAs
seen during the earlier stages of erythroid differentiation
investigated in these studies and the microRNAs reported here
in mature erythrocytes. This similarity indicates that the micro-
RNAs present in mature erythrocytes are likely to originate from
cells in earlier differentiation stages prior to nuclear exclusion and
persist in the mature erythrocyte after terminal differentiation.
Erythrocyte miRNA Expression
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2360Figure 5. Poor expression of miR-320 in HbSS cells was associated with defective CD71 downregulation during terminal
differentiation. (A) The histogram of the fluorescent intensity of reticulocytes transfected with unlabeled (black line) or fluorescently-labeled miR-
320 (green line). (B) The miR-320 level in the transfected reticulocytes transfected with mock, synthesized miR-320 or LNA targeting miR-320 was
determined with real-time PCR. (C, D) The percentage of remaining CD71+ cells normalized against the initial percentage after in vitro differentiation
at indicated time points after transfection with either scrambled LNA or miR-320 knock down LNA. (E) Cell numbers of reticulocytes (left) and
erythrocytes (right) 24 hours after transfection with treatments blocking indicated microRNAs were shown. (F). The reporter activities when empty
vector or miR-451 and miR-320 expression constructs were co-transfected into K562 cells with respective indicator plasmids containing duplicated
copies of sequences identical to miR-451 and mIR-320. (G) The over-expression of miR-320, but not miR-451 or empty vector, in K562 can suppress a
reporter construct containing the 39UTR of CD71. This suppression was abolished when three nucleotides in the miR-320 predicted target site were
mutated as indicated in the 39UTR of CD71. (H) Overexpression of miR-320 led to lower levels of CD71 in K562 cells 48 hours after transfection.
doi:10.1371/journal.pone.0002360.g005
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erythrocytes may be due to the longer half-life and slower decay
kinetics of specific microRNAs. Our results indicated that
microRNAs still exist in the functional form in reticulocytes,
consistent with previous study [30]. The immediate precursor of
reticulocytes, orthochromatic normoblasts, still contains nuclei.
Since the reticulocyte stage lasts for 40 hours [1], it is conceivable
that the reticulocyte microRNA synthesized in the orthochromatic
normoblast become processed, fed into the maturation pathways
and persist in a functional form in reticulocytes. These microRNAs
may persist in the mature erythrocytes after the terminal
differentiation.
The main functional mechanism of microRNAs is through the
post-transcriptional regulation of their target mRNA via mRNA
degradation or translation inhibition [11]. What are the potential
roles for microRNAs in mature erythrocytes, a cell type with
limited target mRNA and translation activity? What is the clinical
relevance for genomic analysis of erythrocyte microRNAs? First,
these erythrocyte microRNAs are likely to play important
regulatory roles during the earlier stages of erythropoiesis, as late
as the reticulocyte. Translational activities are still present in the
reticulocyte stage, and our results also clearly demonstrate a
functional role of microRNAs in these cells during terminal
differentiation of reticulocytes. This observation are consistent
with a recent study of recapitulating the microRNA-mediated
translation repression in reticulocyte cell lysates [30]. Thus, the
microRNA composition captured in circulating erythrocytes is the
balance between microRNA accumulation from earlier differentia-
tion stages and the subsequent microRNA decay in the remaining
erythrocytes exposed to various physiological and pathological
conditions. Many other studies have highlighted the functional
importanceofseveralmicroRNAs(e.g.miR-221,-222,-451and-24)
during various stages of erythroid differentiation [16,20,31]. Second,
erythrocyte microRNAs may play a direct role in the de-adenylation
and degradation of mRNA during erythrocyte terminal differenti-
ation as suggestedbyseveralstudies [32–34].Third,itispossible that
microRNAs play a role in the host-pathogen interaction between
erythrocyteandmalaria parasites,given that human microRNAsare
found in the malaria parasites P. falciparum [8]. Similar involvement
of microRNAs in the host-pathogen interaction was shown for host
microRNAs affecting the growth and propagation of pathogen
[35,36] as well as pathogen-encoded microRNAs impacting host
cellular physiology [37–39]. In our analysis, HbSS erythrocytes have
averyhighlevelofmiR-451,whichwasfoundbetranslocatedintoP.
falciparum. This observation leads to the possibility that microRNA
composition may contribute to the malaria resistance notes for sickle
cell erythrocytes [40,41]. Finally, microRNAs may have additional
functional roles in erythrocytes via a mechanism independent of
mRNAtargeting as suggestedinourobservation that theblockage of
mIR-320 leads to decreased erythrocyte survival.
The differential expression of erythrocyte microRNA may also
lead to novel insights into human erythrocyte diseases. We observed
a dramatic and significant difference between microRNA expres-
sions in mature HbSS and HbAA erythrocytes; partly because of
HbSS erythrocytes are younger than HbAA erythrocytes in their
microRNA expression pattern, consistent with their shorter lifespan.
These differences are likely to provide additional information about
the disease phenotypes, similar to the miR-320::CD71 connection
established inourcurrentstudy.Linkage ofparticularmicroRNAsto
particular SCD disease phenotypes offers the potential not only to
develop useful biomarkers as suggested in a recent review [42], but
also to generate testable biological hypotheses and relevant
pathological insights based on these microRNAs and their predicted
target mRNAs. This line of research can lead to an enhanced
understandingoftherelevantpathophysiologicalmechanismsaswell
as suggest treatments tailored for individual patients. It is important
to expand these studies to a larger cohort of patients with detailed
analysis of their biochemical parameters and clinical phenotypes to
determine the robustness and stability of the various subtypes and
their connection with genetic polymorphisms and other genetic
parameters. We expect that similar use of microarrays and advanced
bioinformatics will greatly enhance our understanding of patho-
physiological mechanisms in various erythroid diseases involving
abnormalgeneticregulationoferythropoiesis(i.e.,aplasticanemiaor
polycythemia vera), as well as erythrocyte-related dysfunction or
hemoglobinopathies (i.e., hemolytic anemia, sickle cell disease).
Without novel mRNA synthesis, post-transcriptional regulation
is probably the main mechanism for gene regulation in enucleated
cells (reticulocytes, platelets, and erythrocytes). Given the pro-
grammed transcriptional arrest with nuclear exclusion in devel-
oping erythroid cells, significant gaps sometimes exist between the
time of mRNA synthesis and actual translation. RNA stability and
translation control are therefore tightly regulated to ensure proper
control of RNA stability and protein synthesis [43], both of which
are likely to be regulated by microRNAs. For example, the post-
transcriptional control of CD71 is mediated by the actions of iron
regulatory proteins (IRP1 and IRP2) in response to iron levels
[21]. The loss of surface expression of CD71 during erythrocyte
terminal differentiation was thought to be caused by its release/
secretion by exosomes [44]. Our findings suggest that microRNAs
are also involved in the reticulocyte terminal differentiation
process. Since miR-320 expression does not change during the
transition between reticulocyte and erythrocytes, its upregulation is
not likely to be a trigger for the loss of CD71 expression. Instead,
miR-320 is likely to fine tune the translational activities of CD71 in
reticulocytes and contribute to its loss of CD71 surface expression
together with the exosome release. MicroRNA-mediated repres-
sion can also be regulated by interactions between miRNA/
Argonaute complexes with RNA-binding proteins that relocate
from different subcellular compartments during stress or differen-
tiation [45]. Many additional mRNAs encode proteins with
important regulatory roles in erythropoiesis are also predicted
targets of erythrocyte microRNAs [24] and their interactions
deserve further exploration in the context of various physiological
and pathological adaptations of erythrocyte diseases.
Materials and Methods
Human blood collection, mature erythrocyte purification
and cell lines
This study was conducted with the approval of the Duke
University Institutional Review Board (IRB), and informed
consent from each donor was obtained. Blood was obtained by
venipuncture and collected into sodium citrate-containing tubes.
Leukocytes were first removed by a PALL PurecellNeo filter (Pall
Biomedical Co, NY). The filtrate was separated in a Ficoll-
hypaque gradient to eliminate remaining leukocytes and platelets
and further leukocyte and reticulocyte depletion using antibody-
conjugated magnetic beads (conjugated to CD45 [leukocyte
common antigen, LCA] and CD71 [transferrin receptor]
antibodies (Miltenyi Biotec, CA). Alternatively, whole blood was
subjected to Ficoll-hypaque gradient centrifugation to remove
platelets and leukocytes. Packed erythrocytes were then subjected
to arabinogalactan density gradient (Larex, MN), comprising three
layers—1.085, 1.090, and 1.095 g/ml, to separate reticulocytes
from mature erythrocytes, which migrated to the high density
layer and were collected for RNA extraction. The purity of the
resulting erythrocytes was evaluated with FACS for surface
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receptor), CD16 (FccRIII) and CD45 (LCA) with fluorescently
labeled antibodies (Pharmingen, CA). To obtain reticulocytes used
for terminal differentiation assays and gene expression studies,
packed erythrocytes obtained from leukocyte-removal filtrate were
incubated with CD71-MACS beads (Miltenyi). After washing with
staining buffer (Hanks’ balanced salt solution with 2% FCS and
0.02% NaN3), CD71+ reticulocytes were enriched with autoMACS
by POSSEL_S mode, immunostained with FITC-conjugated CD71
antibodies and positive cells sorted by FACS. The K562 cells (from
Dr. Murat Arcasoy) were maintained in RPMI supplemented with
10% fetal calf serum, glutamine and antibiotics.
RNA extraction, electrophoresis, RT-PCR analysis, and
Northern blot analysis. Total RNA was extracted using the
mirVana microRNA Isolation Kit (Ambion, TX). For northern
blot analyses, 20 mg of total RNA were separated in 15% TBE-
urea polyacrylamide gel (Bio-Rad, CA), and electro-transferred
onto Hybond-N+ (Amersham Biosciences, UK) membranes. The
blot was then probed with end-labeled DNA probes
complementary to each indicated microRNAs or U6 RNA in
Express-hyb buffer (Clontech, CA) at 37uC.
Analysis of microRNA expression by microarrays
For microRNA expression profiling by microarray, total RNA
samples were size-fractionated and cleaned with the flashPAGE
Fractionator (Ambion, TX) to collect RNAs smaller than 40
nucleotides. These samples then were labeled with the mirVana
microRNA Labeling Kit (Ambion) according to the manufacture’s
instructions [46]. Erythrocyte and K562 small RNAs were labeled
with Cy5; while 293T small RNAs were labeled with Cy3 as
common reference for all samples. The fluorescently labeled
microRNAs were mixed with 36microRNA Hybridization Buffer
(Ambion) and heated at 95uC for 3 min before hybridizing with
the printed microRNA microarrays for 12–16 h in a 42uC water
bath in sealed cassettes. Following hybridization, the slides were
washed, dried and scanned on a GenePix 4000B Array Scanner
(Axon, CA). Array images were analyzed using the GenePix Pro
5.0 software (Axon) and submitted into the Duke Microarray
Database (DMD). Data were normalized globally per array, such
that the average LogRatio was 0 after normalization. All data used
for analysis had an average intensity 2.5 fold above local
background, and a regression ratio .0.6 before further filtering
based on indicated variations among different samples. Hierar-
chical clustering was performed by average linkage using
uncentered Pearson correlation [47]. Microarray data has been
submitted into GEO database with accession number GSE11060
and available on the supplemental website (URL: http://data.
genome.duke.edu/RBC).
Expression profiling of microRNA using multiplexing RT-
PCR assays
The 192-plex RT-PCR assays that were developed for profiling
of 192 individual human microRNAs were used to perform
microRNA profiling with 30 ng of total RNA from each RBC/
reticulocyte samples following the three-step protocols described
previously [17]. Briefly, step 1 is a multiplexed reverse transcrip-
tion reaction which reverse transcribes targeted microRNAs into
cDNAs in a single reaction using 192 microRNA-specific stem-
loop RT primers; step 2 is a multiplexed PCR reaction with 192
sets of microRNA-specific forward primers and a universal reverse
primer that amplifies the cDNA products to provide enough
samples for step 3. Linear amplification was achieved with 14 PCR
cycles. Step 3 is done as simultaneous, individual single-plex
TaqManH real-time PCR reactions to monitor the abundance of
each microRNAs after the multiplexed RT-PCRs. Real-time PCR
was performed on an AB 7900 HT Sequence Detection System in
a 384-well plate format, with the temperature regime consisting of
a hot start at 95uC for 10 min, followed by 40 amplification cycles
composed of 95uC for 15 s, and 60uC for 1 min. The real-time
PCRs for each microRNAs were run in duplicates. Out of 192
microRNA targets, only 189 assays lead to expression information
since three assays (miR-16, -124a and -130b) had technical issues
and were not included in the analysis. MiR-152 was chosen as the
endogenous control for normalization across different samples
based on two reasons: 1) the level of miR-152 does not change
during erythroid differentiation [14]; 2) has-miR-152 showed the
least standard deviation (Stdev=0.68) across 40 tissues in a global
microRNA profiling study using 210 microRNA TaqMan assays
(Applied Biosystems, unpublished data). A 2DCt (=Ct_microR-
NA2Ct_miR-152, Ct: cycle of threshold) was calculated as an
equivalent of normalized relative gene expression level for the
microRNAs being analyzed and used for hierarchical clustering.
In vitro maturation assays of reticulocytes and miR-320
knockdown
The reticulocyte in vitro maturation assay was described previously
[22]. The CD71+ young reticulocytes were isolated from leukode-
pletion-filtered erythrocytes with CD71 microbeads using auto-
MACS
tm Separator. Flow cytometry and new Methylene Blue
staining was performed to determine the purity of the isolated cells.
The purified reticulocytes were then cultured in RPMI supplement-
ed with 10% fetal bovine serum and 50% autologous plasma in a
humidifiedatmosphereofcontaining5%CO2.LockedNucleicAcid
(LNA) oligonucleotides against miR-320, mir-20a and scrambled
control sequence (Exiqon, Denmark) were individually diluted in
Opti-MEMand mixed with diluted Lipofectamine 2000 (Invitrogen)
for30 minatroomtemperaturebeforetransfectingintoreticulocytes
at a final concentration of 33 nM. Transfection medium was
replaced 6 hours post-transfection with the differentiation media
composed of RPMI containing 10% FCS and 50% autologous
plasma. CD71 expression levels of transfected cells were analyzed by
FACS at indicated time after transfection.
Cloning of CD71 reporter constructs and luciferase assays
The 39UTR of the CD71 was amplified from a K562 cDNA
with a pair of primers (forward: atgtgatacccatagcttcc; reverse:
ggcttagatctcatttggag) and cloned into the XbaI site downstream of
firefly luciferase gene in the pGL3-control (Promega, Wisconsin).
The CD71 39UTR miR-320 mutant reporters were constructed
with QuikChangeH II Site-Directed Mutagenesis Kits (Stratagene,
CA), which created three base pair changes in the miR-320 seed
sequence-targeted regions (underlined) (CTAGATGTCTT-
TAGGCAGGATCCTTTAA to replace CTAGATGTCTT-
TAGGCAGCAGCTTTTAA). To assess the effect of miR-320
on CD71 39UTR activity, expression constructs encoding miR-
320 and miR-451 were inserted into a CMV-based pcDNA3
cloning vector (Invitrogen, CA). The following primers were used
to amplified the expression constructs from the genomic DNA of
K562 cells and cloned into the XhoI and EcoRI site of pcDNA3:
miR-320 (forward: ccgaattccaggaaccagacagggacgc; reverse:
ccctcgagccgactcttaagtccaggtc) and miR-451 (forward: ccgaattca-
cagtgcttttcaagccatgc; reverse: ccctcgagatcctcctgccttggcctctg). The
functions of these expression constructs have been confirmed by
their ability to specifically repress pGL3 luciferase ‘‘sensor’’
constructs comprising two copies of the perfect matched
sequences. K562 cells were cotransfected with 1 mg of indicated
reporter (CD71 39UTR or mutCD71 39UTR), 50 ng renilla
luciferase construct and 2 mg of indicated microRNA expression
Erythrocyte miRNA Expression
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After 48 hour, the transfected cells were washed and lysed with the
passive lysis buffer (Promega). The luciferase activities (both firefly
and renilla luciferase) present in the cell lysates were then
determined by Luminometer (Berthold Technology, Germany).
The relative reporter activities were obtained by normalization of
firefly to the renilla luciferase activities determined in the same
lysates with the Dual-Glo Luciferase Assay (Promega).
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Figure S1 The percentage change of indicated parameters
(MHC, MCHC) compared with the corresponding parameter at
time zero during the process of terminal differentiation in vitro.
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Table S1 The mRNA targets for miR-320 predicted by
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